Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

18

Revenue 2017

Epclusa

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Epclusa was produced by Gilead Sciences.

Deal Watch October 2018

In other news from Gilead, the company has created a new subsidiary, Asegua Therapeutics, which will launch authorised generic versions of Epclusa and Harvoni, Gilead’s treatments for hepatits C virus

AbbVie sues NHS England over hep C procurement

AbbVie sues NHS England over hep C procurement treatment – as well as follow-up combinations such as Harvoni (sofosbuvir/ledipasvir) as well as Epclusa (sofosbuvir/velpatasvir) that was effective against all HCV genotypes.

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

Gilead gets OK for three-in-one hep C therapy in US

Gilead gets OK for three-in-one hep C therapy in US The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir - the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa - as well as ... Sovaldi and follow-ups Harvoni and

Two new hepatitis C therapies fast-tracked in Europe

Two new hepatitis C therapies fast-tracked in Europe It is dosed once daily as three oral tablets and is being billed as a rival to Epclusa, which is dosed over 12 weeks in all patients. ... Analysts at Leerink have previously predicted that combined sales of Harvoni, Sovaldi and Epclusa will be $2.5bn a

1 2 3 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics